Trials / Completed
CompletedNCT00863551
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 65 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trospium Chloride | Extended release, 60 mg, oral daily |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-03-18
- Last updated
- 2016-02-26
- Results posted
- 2011-12-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00863551. Inclusion in this directory is not an endorsement.